Diurnal is now Neurocrine UK

Information on Alkindi® (hydrocortisone granules in capsules for opening) for Patients

  1. Home
  2. Information for patients
  3. Information on Alkindi® (hydrocortisone granules in capsules for opening) for Patients

Direct Markets

Information for Italian Patients

Informationen für deutsche Patienten

Information for Austrian Patients

Partnerships

Neurocrine UK works with a number of partners in countries where it does not market its products directly.

PartnersType of contract and productPartner Territories
alt-textEton PharmaceuticalsLicence for Alkindi SprinkleUnited States
alt-textEffRxLicence for AlkindiSwitzerland
alt-textFrostPharmaMarketing and distribution agreement for AlkindiNordics
alt-textConsilient Health / Goodlife PharmaMarketing and distribution agreement for AlkindiNetherlands
alt-textEr-KimMarketing and distribution agreement for AlkindiBulgaria, Romania, Greece & Turkey
alt-textMedomieMarketing and distribution agreement for AlkindiIsrael
alt-textExCEEd OrphanMarketing and distribution agreement for AlkindiCroatia & Slovenia

Information for Czech Patients

Neurocrine Group Ltd (Company Number: 09846650) and its subsidiary, Neurocrine UK Ltd (Company Number: 05237326) are companies registered in England and Wales. Registered Offices: Cardiff Medicentre, Heath Park, Cardiff, CF14 4UJ, UK.

©2025 Neurocrine UK Ltd. All rights reserved
Terms of use | Privacy policy

Date of preparation: October 2025
Code: CORP-GB-0098